Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes

The Journal of Clinical Endocrinology and Metabolism
John DupréThomas J McDonald

Abstract

Exendin-4 is a reptilian peptide that activates the mammalian receptor for truncated glucagon-like peptide 1 (tGLP-1) with relatively prolonged actions. Exendin-4 and tGLP-1 can reduce blood glucose levels by stimulating insulin secretion, inhibiting glucagon secretion, and delaying gastric emptying. We tested a range of doses of exendin-4 on postcibal glycemic excursions in nine volunteers with type 1 diabetes, all with negligible endogenous insulin secretion, in paired comparisons with vehicle in at least six volunteers with each of six doses. We established a side effect-free dose and an appropriate antecibal time for sc administration of exendin-4. Subsequently, exendin-4 was administered 15 min before breakfast, with usual insulin, to eight of the volunteers. Acetaminophen was ingested with the meal as an indicator of gastric emptying. The mean plasma glucose excursion was reduced by 90%, falling into the normal range, after breakfast, whereas plasma pancreatic polypeptide, glucagon, and acetaminophen levels were reduced, and insulin levels were not affected. Thus, normalization of postcibal glycemia was associated with delayed gastric emptying and suppression of glucagon secretion, without increased secretion or blood lev...Continue Reading

Citations

Dec 17, 2008·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Yu ZhangWen Ye
Jan 2, 2007·Southern Medical Journal·Nasser Mikhail
Apr 26, 2008·Diabetes, Obesity & Metabolism·Kasper AaboeJens Juul Holst
Aug 17, 2011·Diabetes, Obesity & Metabolism·D D'Alessio
May 22, 2008·American Journal of Physiology. Endocrinology and Metabolism·Viorica IonutRichard N Bergman
Oct 23, 2009·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Elisabeth L RaabRebecca A Simmons
Aug 15, 2012·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Wenbin LiDongmei Xu
Dec 19, 2008·Pediatric Research·Vandana S Raman, Rubina A Heptulla
Jan 21, 2012·The Review of Diabetic Studies : RDS·Mikkel ChristensenFilip K Knop
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Radha AndukuriMarc Rendell
Apr 12, 2014·Nutrition Research Reviews·Laura MarroquíIvan Quesada
Oct 23, 2013·Canadian Journal of Physiology and Pharmacology·Sawsan M Al LafiAnwar B Bikhazi
Mar 23, 2006·Medizinische Monatsschrift für Pharmazeuten·Annemarie Musch, Susanne Heinzl
Dec 3, 2013·Expert Opinion on Pharmacotherapy·Johnny Ludvigsson
Sep 5, 2015·Expert Opinion on Pharmacotherapy·Kashif M Munir, Stephen N Davis
Nov 25, 2011·Expert Opinion on Investigational Drugs·Alan J Garber
Jul 25, 2006·Expert Opinion on Investigational Drugs·Claudio GonzálezGuillermo Di Girolamo
Sep 24, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jang Kyoung KimYong-Hee Kim
Mar 16, 2013·Diabetes Research and Clinical Practice·K V S Hari KumarPitambar Prusty
Sep 17, 2011·Drug Discovery Today·Chen S Suen, Paul Burn
Sep 21, 2011·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Jongoh KimMaria Jose Redondo
Jan 11, 2011·Biochemical and Biophysical Research Communications·Hiromasa GotoHirotaka Watada
Nov 26, 2009·Pharmacology & Therapeutics·Abd A TahraniAnthony H Barnett
Jul 8, 2009·Drug Discovery Today·Jennifer SherrWilliam V Tamborlane
Oct 10, 2007·Clinics in Geriatric Medicine·Paul KuoMichael Horowitz
Mar 2, 2016·Expert Opinion on Biological Therapy·Thomas Fremming DejgaardSten Madsbad
Nov 23, 2005·Pediatric Clinics of North America·Marianna RachmielDenis Daneman
Nov 23, 2005·Pediatric Clinics of North America·Diego Ize-Ludlow, Mark A Sperling
Nov 23, 2005·Pediatric Clinics of North America·Michael J HallerDesmond Schatz
Mar 31, 2016·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Senay TopsakalSümeyra Kayan
Sep 18, 2013·Diabetes, Obesity & Metabolism·L DingC Mathieu
Jul 19, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·P George, R J McCrimmon
Aug 22, 2006·Metabolism: Clinical and Experimental·Marc S Rendell, Lois Jovanovic
Nov 4, 2016·Pediatric Diabetes·Fida Bacha, Sara Klinepeter Bartz
Sep 24, 2005·Annals of Medicine·C Mark B Edwards
Apr 9, 2015·Nature Reviews. Endocrinology·Jonathan E Campbell, Daniel J Drucker
Dec 3, 2014·Diabetes & Metabolism·S ChonJ-F Gautier
May 21, 2013·Cell Metabolism·Jonathan E Campbell, Daniel J Drucker
Dec 12, 2012·European Journal of Pharmacology·Yoichiro HirataMasataka Sata
Oct 31, 2012·Archives of Oral Biology·Ana Luyza Domingues da Silva FariaEduardo José Caldeira
Mar 25, 2010·Diabetes Care·Vandana S RamanRubina A Heptulla

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.